Role of glutamine in cancer: Therapeutic and imaging implications

Kartik N. Rajagopalan, Ralph J. DeBerardinis

Research output: Contribution to journalArticle

77 Citations (Scopus)

Abstract

Metabolic imaging has great clinical potential in cancer because perturbations of metabolism are common hallmarks of malignant cellular transformation. Novel imaging strategies focused on glutamine could provide a valuable complement to 18F-FDG PET, because glutamine complements glucose in the metabolic platforms that support tumor growth at the cellular level. Furthermore, recent work has demonstrated that distinct aspects of glutamine metabolism are under the control of oncogenes and tumor suppressors. It is plausible that imaging glutamine metabolism could predict both the presence of specific transforming mutations in the tumor and the sensitivity to therapeutic agents designed to target glutamine use. Here, we review the essential aspects of glutamine metabolism in cancer cells and discuss opportunities for imaging in cancer patients.

Original languageEnglish (US)
Pages (from-to)1005-1008
Number of pages4
JournalJournal of Nuclear Medicine
Volume52
Issue number7
DOIs
StatePublished - Jul 1 2011

Fingerprint

Glutamine
Neoplasms
Therapeutics
Fluorodeoxyglucose F18
Oncogenes
Glucose
Mutation
Growth

Keywords

  • Glutamine
  • Metabolism
  • Oncology
  • PET
  • Warburg effect

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Role of glutamine in cancer : Therapeutic and imaging implications. / Rajagopalan, Kartik N.; DeBerardinis, Ralph J.

In: Journal of Nuclear Medicine, Vol. 52, No. 7, 01.07.2011, p. 1005-1008.

Research output: Contribution to journalArticle

@article{de9fbb0551414b34918d4a9a13b0a6dc,
title = "Role of glutamine in cancer: Therapeutic and imaging implications",
abstract = "Metabolic imaging has great clinical potential in cancer because perturbations of metabolism are common hallmarks of malignant cellular transformation. Novel imaging strategies focused on glutamine could provide a valuable complement to 18F-FDG PET, because glutamine complements glucose in the metabolic platforms that support tumor growth at the cellular level. Furthermore, recent work has demonstrated that distinct aspects of glutamine metabolism are under the control of oncogenes and tumor suppressors. It is plausible that imaging glutamine metabolism could predict both the presence of specific transforming mutations in the tumor and the sensitivity to therapeutic agents designed to target glutamine use. Here, we review the essential aspects of glutamine metabolism in cancer cells and discuss opportunities for imaging in cancer patients.",
keywords = "Glutamine, Metabolism, Oncology, PET, Warburg effect",
author = "Rajagopalan, {Kartik N.} and DeBerardinis, {Ralph J.}",
year = "2011",
month = "7",
day = "1",
doi = "10.2967/jnumed.110.084244",
language = "English (US)",
volume = "52",
pages = "1005--1008",
journal = "Journal of Nuclear Medicine",
issn = "0161-5505",
publisher = "Society of Nuclear Medicine Inc.",
number = "7",

}

TY - JOUR

T1 - Role of glutamine in cancer

T2 - Therapeutic and imaging implications

AU - Rajagopalan, Kartik N.

AU - DeBerardinis, Ralph J.

PY - 2011/7/1

Y1 - 2011/7/1

N2 - Metabolic imaging has great clinical potential in cancer because perturbations of metabolism are common hallmarks of malignant cellular transformation. Novel imaging strategies focused on glutamine could provide a valuable complement to 18F-FDG PET, because glutamine complements glucose in the metabolic platforms that support tumor growth at the cellular level. Furthermore, recent work has demonstrated that distinct aspects of glutamine metabolism are under the control of oncogenes and tumor suppressors. It is plausible that imaging glutamine metabolism could predict both the presence of specific transforming mutations in the tumor and the sensitivity to therapeutic agents designed to target glutamine use. Here, we review the essential aspects of glutamine metabolism in cancer cells and discuss opportunities for imaging in cancer patients.

AB - Metabolic imaging has great clinical potential in cancer because perturbations of metabolism are common hallmarks of malignant cellular transformation. Novel imaging strategies focused on glutamine could provide a valuable complement to 18F-FDG PET, because glutamine complements glucose in the metabolic platforms that support tumor growth at the cellular level. Furthermore, recent work has demonstrated that distinct aspects of glutamine metabolism are under the control of oncogenes and tumor suppressors. It is plausible that imaging glutamine metabolism could predict both the presence of specific transforming mutations in the tumor and the sensitivity to therapeutic agents designed to target glutamine use. Here, we review the essential aspects of glutamine metabolism in cancer cells and discuss opportunities for imaging in cancer patients.

KW - Glutamine

KW - Metabolism

KW - Oncology

KW - PET

KW - Warburg effect

UR - http://www.scopus.com/inward/record.url?scp=79960329041&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960329041&partnerID=8YFLogxK

U2 - 10.2967/jnumed.110.084244

DO - 10.2967/jnumed.110.084244

M3 - Article

C2 - 21680688

AN - SCOPUS:79960329041

VL - 52

SP - 1005

EP - 1008

JO - Journal of Nuclear Medicine

JF - Journal of Nuclear Medicine

SN - 0161-5505

IS - 7

ER -